Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 127
- 试验地点
- 1
- 主要终点
- Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task
研究概览
简要总结
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action. We have recently shown that the stimulant methylphenidate (MPH) and the non-stimulant atomoxetine (ATX) produce clinical improvement via a common mechanism in motor cortex, and distinct actions in frontostriatal and midline cingulate-precuneus regions. These exciting findings offer a window into the common and unique neurophysiological mechanisms of response to stimulant and non-stimulant treatments. However, the interpretation and clinical utility of these results would be greatly enhanced by in-depth investigation of the impact of the two treatments on relevant neural networks, and analyses which evaluate whether improvement is achieved via normalization or other adaptive changes in brain function.
详细描述
The specific aims of this project are to use functional magnetic resonance imaging (fMRI) to determine the significance of activation changes over treatment related to clinical improvement, and the impact of treatment on neural connectivity within and between the anti-correlated frontostriatal 'task-positive' circuit and cingulate-precuneus 'task-negative' network. Our central hypotheses are that clinical improvement is associated with: (i) normalization of reduced connectivity of regions within the 'task-positive' network, with resultant increased inhibition of motor cortex, and (ii) normalization of low task-related connectivity in regions within the task-negative network for MPH and the 'task-positive' network for ATX.
This research proposes to test a model which posits a neurophysiological basis of mechanisms of response to stimulant and non-stimulant medications, and fits with our long term objectives of being able to match treatments to individual patients. Testing this model requires large samples of youth scanned using fMRI before and after treatment, and matched healthy controls also scanned twice. We will use an innovative network-based approach to study the effects of treatment, building on results from our current fMRI treatment study, and incorporating new theoretical approaches to understanding ADHD and its treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 7 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •General inclusion criteria for subjects with ADHD and healthy controls are:
- •aged 7-17 years;
- •Wechsler Intelligence Scale for Children (WISC) scores ≥ 75;
- •informed consent and assent to study participation.
- •Specific inclusion criteria for youth with ADHD are:
- •diagnosis of ADHD, any subtype, determined by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Present and Lifetime Versions (K-SADS-PL);
- •ADHD Rating Scale-IV-Parent Version: Investigator Administered (ADHD-RSIV) total score ≥ 1.5 SD above age and gender means for subtype
- •Clinical Global Impressions-ADHD-Severity (CGI-S) score > 4;
- •ADHD must be the primary diagnosis and focus of treatment, and the treatments offered in the study must not be contraindicated for the comorbid disorder.
排除标准
- •General exclusion criteria are:
- •history of head injury with loss of consciousness or any CNS disease that is likely to affect brain function;
- •diagnosis of autism or pervasive developmental, psychotic, major mood, and Tourette's disorder;
- •alcohol or drug abuse in the past 3 months or a positive urinary toxic screen on initial evaluation;
- •use of psychotropic medication within 2 weeks of the study (8 weeks for fluoxetine);
- •pre-existing medical or psychological condition which precludes being in the scanner (e.g., claustrophobia, morbid obesity);
- •metal in the body that precludes scanning (e.g., braces, metal plate);
- •positive urine pregnancy test.
- •Specific exclusion criteria for the treatment trial include:
- •previous unsuccessful trial of MPH or ATX that was adequately dosed (≥ 1 mg/kg for MPH or 1.0 mg/kg for ATX) and of adequate duration (≥ 4 weeks);
- •abnormal findings on physical exam, or vital signs
- •pulse and blood pressure > 95% of age and gender mean;
- •inability to swallow capsules;
- •weight is < 20 kg or > 85 kg.
- •Specific exclusion criteria for control youth include:
- •no past history or current diagnosis of any psychiatric disorder, determined by the K-SADS-PL interview;
- •ADHD-RS-IV and CBCL scores for each symptom domain ≤ 1 SD of age and gender means.
研究组 & 干预措施
fMRI scans
Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
干预措施: fMRI scans (Other)
Atomoxetine arm
These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
干预措施: fMRI scans (Other)
Atomoxetine arm
These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
干预措施: Atomoxetine arm (Drug)
Methylphenidate arm
Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
干预措施: fMRI scans (Other)
Methylphenidate arm
Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
干预措施: Methylphenidate arm (Drug)
结局指标
主要结局
Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task
时间窗: Baseline and at 6 weeks
Comparison of Go-Nogo at 6 weeks from baseline. Performance on a go-nogo task inside the scanner (fMRI). In the go/no-go task, participants respond to certain stimuli ("go" stimuli) and make no response for others ("no-go" stimuli).
次要结局
- Finger Windows(baseline and at 6 weeks)
- Continuous Performance Test (CPT)(baseline and at 6 weeks)
- Adult Attention Deficit Hyperactivity Disorder Investigator Symptom Rating Scale (ADHD-RS)(8 weeks)
- Clinical Global Impressions-Severity (CGI-S)(up to 6 weeks)
- Response Time in Attention Networks Test (ANT)(baseline and at 6 weeks)
- Digit Span(baseline and at 6 weeks)
研究者
Jeffrey Newcorn
Director Division of Child and Adolescent Psychiatry, Associate Professor Psychiatry and Pediatrics, Medical Director Center for Excellence for ADHD and Related Disorders
Icahn School of Medicine at Mount Sinai